SU-DHL-6Homo sapiens (Human)Cancer cell line
Also known as: SUDHL6, SuDHL6, SU-DHL6, SUDHL-6, SuDHL-6, Sudhl-6, SUD6, Stanford University-Diffuse Histiocytic Lymphoma-6, DHL-6, DHL6
Quick Overview
SU-DHL-6 is a human B-cell lymphoma cell line derived from diffuse large B-cell lymphoma.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_2206 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peritoneal effusion[UBERON:UBERON_0001268] |
Donor Information
| Age | 43 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Diffuse large B-cell lymphoma germinal center B-cell type |
|---|---|
| Lineage | Lymphoid |
| Subtype | Diffuse Large B-Cell Lymphoma, NOS |
| OncoTree Code | DLBCLNOS |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000611_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | BCL2 | IGH-BCL2 | - | - | from parent cell line SU-DHL-4 |
| MutationSimple | EZH2 | p.Tyr646Ser (c.1937A>C) (Y641S) | Heterozygous | - | from parent cell line SU-DHL-4 |
| MutationSimple | KMT2D | p.Gln211Ter (c.631C>T) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | KMT2D | p.Glu4712Ter (c.14134G>T) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | TP53 | c.673-2A>C (IVS6-2A>C) | Heterozygous | Splice acceptor mutation | Unknown, Unknown |
| MutationSimple | TP53 | p.Tyr234Cys (c.701A>G) | Heterozygous | - | PubMed=27822414 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Biology and virology of the human malignant lymphomas: 1st Milford D. Schulz Lecture.
Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.
Cancer 43:1-24(1979).
Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse.
Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.
Cancer 37:2158-2176(1976).
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.
Epstein A.L., Levy R., Kim H., Henle W., Henle G.S., Kaplan H.S.
Cancer 42:2379-2391(1978).
Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.
Epstein A.L., Kaplan H.S.
Cancer Res. 39:1748-1759(1979).
Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.
Hecht F.
Cancer Genet. Cytogenet. 14:205-218(1985).
Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
Millar J.L., Catovsky D., Dyer M.J.S.
Blood 85:893-901(1995).
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Aizawa Y., Ueda R., Seto M.
Jpn. J. Cancer Res. 89:712-718(1998).
PTEN gene alterations in lymphoid neoplasms.";
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
Blood 92:3410-3415(1998).
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M.
Nature 403:503-511(2000).
Microarray analysis of B-cell lymphoma cell lines with the t(14;18).
Elenitoba-Johnson K.S.J.
J. Mol. Diagn. 4:123-136(2002).
Serologic detection of diffuse large B-cell lymphoma-associated antigens.
Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H.
Int. J. Cancer 110:563-569(2004).
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Martinez-Climent J.A.
Blood 109:271-280(2007).
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Robetorye R.S., Aguiar R.C.T.
Blood 113:6681-6690(2009).
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Nature 463:88-92(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Kutok J.L., Shipp M.A.
Blood 116:3268-3277(2010).
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.
Blood 117:200-210(2011).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Marra M.A.
Blood 122:1256-1265(2013).
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
J. Virol. 89:713-729(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Leuk. Lymphoma 57:1015-1020(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).